Biogen/BIIB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Biogen

Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.

Ticker

BIIB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Christopher Viehbacher

Employees

7,570

Headquarters

Cambridge, United States

Biogen Metrics

BasicAdvanced
$33B
Market cap
28.11
P/E ratio
$8.00
EPS
-0.02
Beta
-
Dividend rate
$33B
-0.01953
$319.76
$189.44
1.2M
2.096
1.315
41.347
42.99
28.59
3.78%
4.56%
8.04%
5.20%
28.105
3.389
2.153
46.726
25.499
-4.37%
-62.83%
-9.89%
-31.49%

What the Analysts think about Biogen

Analyst Ratings

Majority rating from 36 analysts.
Buy

Biogen Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
17.17% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2.3B
-4.01%
Net income
$393M
57.55%
Profit margin
17.17%
64.15%

Biogen Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.41%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$4.02
$4.36
$3.30
$3.67
-
Expected
$3.77
$3.97
$3.18
$3.45
$4.00
Surprise
6.75%
9.74%
3.66%
6.41%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Biogen stock?

Biogen (BIIB) has a market cap of $33B as of June 15, 2024.

What is the P/E ratio for Biogen stock?

The price to earnings (P/E) ratio for Biogen (BIIB) stock is 28.11 as of June 15, 2024.

Does Biogen stock pay dividends?

No, Biogen (BIIB) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next Biogen dividend payment date?

Biogen (BIIB) stock does not pay dividends to its shareholders.

What is the beta indicator for Biogen?

Biogen (BIIB) has a beta rating of -0.02. This means that it has an inverse relation to market volatility.

What is the Biogen stock price target?

The target price for Biogen (BIIB) stock is $283.95, which is NaN% below the current price of $. This is an average based on projections from 29 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Biogen stock

Buy or sell Biogen stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing